Scarica l'app Stockscreener
5.39
4.05%
0.21
Protara Therapeutics Inc Borsa (TARA) Ultime notizie
Velan Capital Investment Management LP Increases Stake in Protara Therapeutics Inc - GuruFocus.com
Flatiron-based drug company raises $100M for cancer treatment - Crain's New York Business
Protara Therapeutics: Rising From The Ashes (NASDAQ:TARA) - Seeking Alpha
Protara Therapeutics Raises $100M in Stock Offering - TipRanks
Protara Announces Closing of $100 Million Public Offering - GlobeNewswire
SEC Form 424B5 filed by Protara Therapeutics Inc. - Quantisnow
Protara Therapeutics Secures Massive $100M Public Offering to Advance TARA-002 Development - StockTitan
Protara Therapeutics: Carving New Roads In Bladder Cancer (TARA) - Seeking Alpha
Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst - Seeking Alpha
Protara announces public offering to fund clinical programs By Investing.com - Investing.com Canada
Protara Therapeutics drops 6%, prices $100M offering - MSN
Protara Announces Pricing of $100 Million Public Offering - citybiz
Protara Therapeutics Launches Massive $100M Public Offering to Advance TARA-002 Development - StockTitan
Protara Announces Proposed Public Offering - The Manila Times
Protara announces public offering to fund clinical programs - Investing.com
Protara Therapeutics Launches Public Offering to Advance TARA-002 Clinical Development - StockTitan
Protara Therapeutics Stock Doubles On Promising Bladder Cancer Trial Data: Retail Buzz Spikes - MSN
HC Wainwright Reiterates Buy Rating for Protara Therapeutics (NASDAQ:TARA) - Defense World
Protara Therapeutics (STU:1KPA) Enterprise Value : €42.66 Mil (As of Dec. 07, 2024) - GuruFocus.com
Protara Therapeutics (NASDAQ:TARA) Earns Buy Rating from Guggenheim - MarketBeat
Protara Therapeutics' (TARA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Institutions profited after Protara Therapeutics, Inc.'s (NASDAQ:TARA) market cap rose US$60m last week but individual investors profited the most - Yahoo Finance
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy - Yahoo Finance
Protara, CG Oncology Tout Promising Bladder Cancer Outcomes - BioSpace
Protera Therapeutics stock remains Buy-rated after promising TARA-002 Phase II results - Investing.com Canada
Protara cell therapy impresses in non-muscle invasive bladder cancer - FirstWord Pharma
TARA stock soars to 52-week high, touches $9.45 amid robust gains - Investing.com Australia
TARA-002 shows promise in bladder cancer trial By Investing.com - Investing.com South Africa
Protara shares spike after cell therapy shows high response rate, no severe side effects in bladder cancer trial - Fierce Biotech
Protara Therapeutics (FRA:1KPA) EV-to-Revenue : (As of Dec. 05, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) 5-Day RSI : 55.72 (As of Dec. 05, 2024) - GuruFocus.com
Stock market news: Arcadia Biosciences +186.66%, Protara Therapeutics +101.69% among top gainers during mid day trading - Business Upturn
Protara, CG climb bladder ladder with SUO cancer findings - BioWorld Online
Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday? - Benzinga
Stock market today: Arcadia Biosciences +153.62%, Protara Therapeutics +133.20% among top gainers in early trading - Business Upturn
Protara Therapeutics Reports Promising Phase 2 Trial Results - TipRanks
Protara Therapeutics shares surge on positive trial results - Investing.com
Protara Therapeutics shares surge on positive trial results By Investing.com - Investing.com UK
Protara Therapeutics, Inc. Announces Positive Results from the Ongoing Phase 2 Advanced Advanced-2 Trial of TARA-002 in Patients with NMIBC - Marketscreener.com
Protara Therapeutics Shares Soar on Positive Data for Bladder Cancer Treatment Trials - MarketWatch
Adf Group Inc Sv (DRX-T) QuotePress Release - The Globe and Mail
Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC - The Manila Times
Protara's TARA-002 Shows Breakthrough 72% Response Rate in Bladder Cancer Trial Results - StockTitan
TARAProtara Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Protara Therapeutics to Host Conference Call and Webcast to - GlobeNewswire
Protara Therapeutics to Present Phase 2 Bladder Cancer Trial Data at Key Oncology Meeting - StockTitan
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Protara Therapeutics (FRA:1KPA) 3-Year FCF Growth Rate : 0.40% (As of Sep. 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) EV-to-Revenue : (As of Nov. 26, 2024) - GuruFocus.com
Protara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation - Simply Wall St
Opaleye Management Inc. Reduces Stake in Protara Therapeutics Inc. - GuruFocus.com
HC Wainwright Analysts Decrease Earnings Estimates for TARA - MarketBeat
Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Up 18.1% in October - MarketBeat
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology - The Manila Times
Protara Therapeutics to Present New Interim Data from Phase - GlobeNewswire
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):